| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCULATIONAHA.107.740324 |
| P698 | PubMed publication ID | 18056526 |
| P50 | author | Eugene Braunwald | Q322114 |
| Gilles Montalescot | Q28468989 | ||
| Andrew L Frelinger | Q55426410 | ||
| Elliott M Antman | Q64496972 | ||
| Dominick Angiolillo | Q72837721 | ||
| Alan D Michelson | Q88284270 | ||
| Joseph M Jakubowski | Q96255992 | ||
| Michelle L O'Donoghue | Q96581274 | ||
| Carolyn F McCabe | Q104737144 | ||
| Sabina A Murphy | Q114308442 | ||
| Stephen D Wiviott | Q114427160 | ||
| Hanoch Hod | Q114444056 | ||
| Franz-Josef Neumann | Q1308604 | ||
| P2093 | author name string | Dietmar Trenk | |
| Debra L Miller | |||
| Richard Cairns | |||
| PRINCIPLE-TIMI 44 Investigators | |||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| clopidogrel | Q410237 | ||
| thrombolysis | Q1931577 | ||
| P304 | page(s) | 2923-2932 | |
| P577 | publication date | 2007-12-03 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | |
| P478 | volume | 116 |
| Q22241922 | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q61806944 | A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies |
| Q64882378 | A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. |
| Q37550156 | A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes |
| Q47763372 | A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching |
| Q37788682 | A comparison of the metabolism of clopidogrel and prasugrel |
| Q37973114 | A comprehensive comparative review of adenosine diphosphate receptor antagonists |
| Q37925028 | A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel |
| Q50276492 | A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. |
| Q34751965 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial |
| Q38475429 | A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel |
| Q57764209 | ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome |
| Q33952693 | Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives |
| Q37998114 | Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines |
| Q30490718 | Acute coronary syndromes: diagnosis and management, part I |
| Q37995859 | Acute coronary syndromes: identifying the appropriate patient for prasugrel |
| Q64988692 | Acute stent thrombosis after a "stroll for fresh air". A case of the smoking gun. |
| Q58768916 | Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis |
| Q38962250 | An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes |
| Q34577974 | An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. |
| Q84705281 | Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention |
| Q38349536 | Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation |
| Q50864337 | Antiplatelet Therapy for Non-ST-Segment Elevation Myocardial Infarction in Complex "Real" Clinical Scenarios: A Consensus Document of the "Campania NSTEMI Study Group". |
| Q64986848 | Antiplatelet Therapy in Acute Coronary Syndrome. |
| Q88239435 | Antiplatelet Therapy in Percutaneous Coronary Intervention |
| Q33395898 | Antiplatelet and anticoagulant drugs in interventional radiology |
| Q38101275 | Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents |
| Q36302146 | Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review |
| Q38079917 | Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes |
| Q58481433 | Antiplatelet drugs |
| Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
| Q37953465 | Antiplatelet options for secondary prevention in acute coronary syndromes |
| Q37684794 | Antiplatelet therapies for the treatment of cardiovascular disease |
| Q37838100 | Antiplatelet therapy and vascular disease: an update. |
| Q38570608 | Antiplatelet therapy in acute coronary syndromes |
| Q46494893 | Antiplatelet therapy in acute coronary syndromes |
| Q37965609 | Antiplatelet therapy in acute coronary syndromes. |
| Q36160606 | Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes |
| Q46359254 | Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel |
| Q38048245 | Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? |
| Q37714189 | Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. |
| Q38117743 | Antiplatelet therapy: new pharmacological agents and changing paradigms |
| Q38384163 | Antiplatelet treatment in essential hypertension: where do we stand? |
| Q38068595 | Antiplatelets in acute coronary syndrome: personal perspectives. |
| Q39147735 | Antithrombotic therapy for patients with STEMI undergoing primary PCI. |
| Q37827870 | Antithrombotic therapy in ST-segment elevation myocardial infarction |
| Q37797795 | Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. |
| Q38172307 | Application of personalized medicine to chronic disease: a feasibility assessment |
| Q26849372 | Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go? |
| Q46635067 | Approaching an age of reason with antiplatelet therapy |
| Q34771381 | Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance |
| Q37311337 | Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. |
| Q37878982 | Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? |
| Q37831317 | Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. |
| Q39121292 | Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion |
| Q35569714 | Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data. |
| Q91864154 | Changing Paradigms of Periprocedural Antithrombotic Therapy in Neuroendovascular Therapy: Analysis of JR-NET 3 |
| Q42932504 | Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders |
| Q91817259 | Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements |
| Q38380465 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes |
| Q35033722 | Clinical evidence of interaction between clopidogrel and proton pump inhibitors |
| Q42822404 | Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention |
| Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
| Q21710717 | Clinical profile of prasugrel, a novel thienopyridine |
| Q37209003 | Clopidogrel and coronary stents: risks and benefits |
| Q83540883 | Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms |
| Q37786639 | Clopidogrel in acute coronary syndrome: implications of recent study findings |
| Q37627874 | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations |
| Q46542883 | Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study |
| Q42003164 | Clopidogrel resistance "Live" - the risk of stent thrombosis should be evaluated before procedures |
| Q37924998 | Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment |
| Q43233667 | Clopidogrel versus prasugrel: times are changing, but not for everyone |
| Q30573045 | Clopidogrel: the data, the experience, and the controversies |
| Q38168199 | Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered |
| Q45783706 | Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. |
| Q38122999 | Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis |
| Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
| Q36688145 | Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial |
| Q41538436 | Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry |
| Q34093139 | Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study |
| Q81101220 | Conducting clinical trials: even more challenges |
| Q56384060 | Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease |
| Q37774825 | Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention |
| Q50179220 | Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). |
| Q48686943 | Correction of prasugrel-related bleeding by prophylactic transfusion of human platelets in a rabbit model. |
| Q41333305 | Cost implications of intraprocedural thrombotic events during PCI. |
| Q35660767 | Critical appraisal of ticagrelor in the management of acute coronary syndrome |
| Q88196076 | Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions |
| Q38578616 | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents |
| Q34382431 | Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents |
| Q26771106 | Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications |
| Q37167506 | Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization |
| Q82999918 | Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q38087381 | Dual antiplatelet therapy in patients with diabetes mellitus: special considerations |
| Q38079124 | Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology |
| Q61671270 | Duración del tratamiento antiagregante en el síndrome coronario agudo |
| Q37953153 | Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. |
| Q45824389 | Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction |
| Q30800602 | Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry |
| Q38592881 | Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users |
| Q37807398 | Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel |
| Q33424820 | Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia |
| Q46184936 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials |
| Q45888145 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation |
| Q42978644 | Elinogrel: pharmacological principles, preclinical and early phase clinical testing |
| Q37979178 | Emerging antiplatelet agents, differential pharmacology, and clinical utility |
| Q37670190 | Emerging drugs for acute myocardial infarction |
| Q37949587 | Emerging therapies for acute coronary syndromes |
| Q41020546 | Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects |
| Q43799381 | Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes |
| Q37988850 | Evolving role of platelet function testing in coronary artery interventions |
| Q38243032 | Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. |
| Q42415858 | GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin |
| Q88842612 | Genetic Determinants of P2Y12 Inhibitors and Clinical Implications |
| Q37882695 | Genetic determinants of on-clopidogrel high platelet reactivity. |
| Q34564576 | Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis |
| Q58688732 | Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route |
| Q48246774 | Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. |
| Q55175923 | High On-Treatment Platelet Reactivity Associated With Prasugrel. |
| Q35758891 | High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel |
| Q38391222 | High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. |
| Q38844348 | High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting |
| Q26824850 | High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance |
| Q42093931 | Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines |
| Q49908712 | Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. |
| Q37434609 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events Aft |
| Q36082585 | Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation |
| Q41023511 | Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study |
| Q33990428 | Implementing genotype-guided antithrombotic therapy |
| Q38025446 | Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel |
| Q38009041 | Improving long-term ACS management: is there a role for the new antiplatelets? |
| Q37498604 | Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel |
| Q42235368 | In search of a better platelet ADP-receptor blocker |
| Q35755253 | Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy |
| Q37076189 | Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study |
| Q37973397 | InforMatrix: ADP antagonists in acute coronary syndromes |
| Q45918033 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. |
| Q42535451 | Intensity of antiplatelet therapy and percutaneous coronary intervention |
| Q44589935 | Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r |
| Q38872380 | Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes? |
| Q46105785 | Ischaemia versus bleeding: the art of clinical decision-making |
| Q98726626 | Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature |
| Q38364982 | Management of antithrombotic therapy in patients undergoing electrophysiological device surgery |
| Q84586782 | Management of non-ST-segment elevation acute coronary syndromes. Introduction |
| Q37930967 | Managing adverse effects and drug-drug interactions of antiplatelet agents |
| Q55649547 | Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. |
| Q37641606 | Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans |
| Q38063289 | Modern antiplatelet agents in coronary artery disease |
| Q37362783 | Monitoring oral antiplatelet therapy: is it justified? |
| Q54957485 | Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. |
| Q38817144 | New directions for pharmacotherapy in the treatment of acute coronary syndrome. |
| Q26824577 | New directions in antiplatelet therapy |
| Q38366950 | Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. |
| Q36676694 | Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a review |
| Q38257119 | Novel antiplatelet agents in acute coronary syndrome |
| Q37958763 | Novel antiplatelet therapies |
| Q37925007 | Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome |
| Q37772417 | Old and new molecular mechanisms associated with platelet resistance to antithrombotics |
| Q52567898 | Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI. |
| Q53523898 | Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. |
| Q37880741 | Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention |
| Q57460606 | Oral antiplatelet agents in cardiovascular disease |
| Q37774826 | Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk |
| Q35141772 | Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview |
| Q39635786 | Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q37969927 | P2Y12 platelet inhibition in clinical practice |
| Q38051192 | P2Y12 receptor: platelet thrombus formation and medical interventions. |
| Q26745619 | P2Y12-ADP receptor antagonists: Days of future and past |
| Q51539033 | P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. |
| Q38012080 | Perioperative antiplatelet management in patients with coronary artery stenting |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
| Q38040698 | Personalizing antiplatelet therapy with clopidogrel. |
| Q61307767 | Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study) |
| Q42164176 | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial |
| Q37590925 | Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials |
| Q38018679 | Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives |
| Q84866784 | Pharmacogenetic guidance for antiplatelet treatment |
| Q37808224 | Pharmacogenetics guided anticoagulation |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q38189810 | Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. |
| Q33685876 | Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases |
| Q43288118 | Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor |
| Q38151563 | Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. |
| Q38065738 | Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. |
| Q38101963 | Pharmacotherapy for the reduction of stent thrombosis |
| Q26861282 | Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists |
| Q37310828 | Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future |
| Q37579228 | Platelet P2Y12 receptor inhibition by thienopyridines: status and future |
| Q37235603 | Platelet activation, and antiplatelet targets and agents: current and novel strategies. |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q38007894 | Platelet function and inhibition in ischemic heart disease |
| Q35174193 | Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective |
| Q36715385 | Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation |
| Q38094681 | Platelet function testing and tailored antiplatelet therapy |
| Q83386220 | Platelet function testing in clinical practice: are we ready for prime time? |
| Q53736763 | Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. |
| Q38132252 | Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know |
| Q45912513 | Point of care platelet function testing in routine neurointerventional care is unjustified. |
| Q37693085 | Poor response to clopidogrel: current and future options for its management |
| Q37809122 | Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management. |
| Q55004314 | Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. |
| Q35204942 | Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study |
| Q46105774 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial |
| Q38380609 | Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study |
| Q37818331 | Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development |
| Q37479088 | Prasugrel for the treatment of patients with acute coronary syndrome |
| Q38336838 | Prasugrel hydrochloride for the treatment of acute coronary syndromes. |
| Q37451509 | Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. |
| Q38012439 | Prasugrel is effective and safe for neurointerventional procedures |
| Q54580380 | Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. |
| Q37905028 | Prasugrel resistance: fact or fiction |
| Q37982427 | Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients |
| Q57252716 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial |
| Q43285495 | Prasugrel versus clopidogrel in primary PCI: considerations of the TRITON-TIMI 38 substudy |
| Q43430172 | Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. |
| Q37907902 | Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? |
| Q98939322 | Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial |
| Q37641320 | Prasugrel: a critical comparison with clopidogrel. |
| Q37579188 | Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q37486601 | Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention |
| Q38998163 | Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy |
| Q51017538 | Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. |
| Q38308207 | Prevention and treatment of atherosclerosis in haemophilia - how to balance risk of bleeding with risk of ischaemic events. |
| Q37984281 | Preventive aspects in peripheral artery disease |
| Q38340126 | Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention |
| Q37089766 | Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions |
| Q55072550 | Recent progress and market analysis of anticoagulant drugs. |
| Q36935879 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial |
| Q37765291 | Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization |
| Q44264585 | Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report |
| Q38153784 | Revascularization strategies in patients with Type 2 diabetes mellitus |
| Q37799470 | Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians |
| Q37809630 | Review: Antiplatelet drugs: what comes next? |
| Q38401281 | Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention |
| Q44751773 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. |
| Q37532491 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease |
| Q30438893 | Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q34182816 | Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study |
| Q38938316 | Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study |
| Q92226447 | Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention |
| Q35176063 | Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease |
| Q30373414 | State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. |
| Q41962888 | Stent thrombosis: incidence, predictors and new technologies |
| Q37198893 | Study of platelet aggregation in acute coronary syndrome with special reference to metabolic syndrome |
| Q38568711 | Switching P2Y12-receptor inhibitors in patients with coronary artery disease |
| Q38009746 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist |
| Q91237478 | Switching between P2Y12 antagonists - From bench to bedside |
| Q36947677 | Switching between thienopyridines in patients with acute myocardial infarction and quality of care |
| Q51151977 | Switching from clopidogrel to prasugrel in patients having coronary stent implantation. |
| Q39224836 | Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience |
| Q50055077 | T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. |
| Q37925009 | TRITON and beyond: new insights into the profile of prasugrel |
| Q51059922 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. |
| Q38076348 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome |
| Q37900470 | The evolution of antiplatelet therapy in cardiovascular disease |
| Q38053481 | The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. |
| Q37923969 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders |
| Q34763870 | The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis |
| Q38603459 | The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review |
| Q35683944 | The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance? |
| Q100504013 | The need of a multicomponent guiding approach to personalize clopidogrel treatment |
| Q38800853 | The pharmacodynamics of antiplatelet compounds in thrombosis treatment |
| Q26801867 | The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 |
| Q37380507 | The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes |
| Q46591786 | The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function |
| Q42285709 | The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. |
| Q37576116 | Thienopyridine therapy and risk for cardiovascular events in secondary prevention |
| Q37838124 | Thienopyridines in Acute Coronary Syndrome |
| Q43192530 | Ticagrelor in ACS: redefining a new standard of care? |
| Q102135395 | Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial |
| Q38557198 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? |
| Q37807874 | Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome |
| Q48163588 | Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome. |
| Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
| Q38016384 | Use of cilostazol in percutaneous coronary interventions |
| Q35373698 | Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? |
| Q37936014 | Variability of clopidogrel response in patients with type 2 diabetes mellitus |
| Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
| Q38005621 | Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? |
| Q85893287 | [Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration] |
| Q83347390 | [Global cardiovascular risk in health care: what else shall patients and doctors talk about?] |
| Q84632274 | [Myocardial revascularization] |
| Q87166270 | [Myocardial revascularization] |
| Q86843930 | [Pharmacogenetics. Clinical relevance in anesthsiology] |
| Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |
| Q22242895 | ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el |
Search more.